UNLABELLED: The aim of this study was to compare the results of somatostatin receptor scintigraphy (SRS) and of radioiodine scintigraphy in patients with metastatic differentiated thyroid carcinoma during L-thyroxine suppression therapy and after withdrawal. Twenty-five patients were studied: 16 patients had papillary cancer and 12 of them had metastatic disease; 9 patients had follicular cancer and 7 of these had known metastases. In 7 patients SRS was performed during thyroxine withdrawal, in 12 during thyroxine therapy within 9 months from radioiodine scintigraphy, in 6 others both during suppression therapy and after withdrawal. SRS was positive in 18 of 25 (72%) patients. It demonstrated lesions in 11 of 13 (85%) patients after thyroxine withdrawal and in 12 of 18 (67%) patients during thyroxine suppression. In 6 patients in whom a direct comparison was made before and after withdrawal, essentially the same information was obtained. Six of 8 (75%) patients with lesions that did not concentrate radioiodine showed uptake of labeled octreotide in these lesions. In 5 of 17 (29%) patients whose tumors concentrated radioiodine, no uptake was found during SRS. CONCLUSIONS: 1) in patients with metastatic differentiated thyroid carcinoma, tumor sites can be visualized using SRS; 2) there is no need to withdraw patients from suppression therapy in order to perform SRS; 3) in some patients whose lesions do concentrate labeled octreotide but not radioiodine, the use of somatostatin analogues labeled with (111)In or [90Y] can provide new therapeutic options.
UNLABELLED: The aim of this study was to compare the results of somatostatin receptor scintigraphy (SRS) and of radioiodine scintigraphy in patients with metastatic differentiated thyroid carcinoma during L-thyroxine suppression therapy and after withdrawal. Twenty-five patients were studied: 16 patients had papillary cancer and 12 of them had metastatic disease; 9 patients had follicular cancer and 7 of these had known metastases. In 7 patientsSRS was performed during thyroxine withdrawal, in 12 during thyroxine therapy within 9 months from radioiodine scintigraphy, in 6 others both during suppression therapy and after withdrawal. SRS was positive in 18 of 25 (72%) patients. It demonstrated lesions in 11 of 13 (85%) patients after thyroxine withdrawal and in 12 of 18 (67%) patients during thyroxine suppression. In 6 patients in whom a direct comparison was made before and after withdrawal, essentially the same information was obtained. Six of 8 (75%) patients with lesions that did not concentrate radioiodine showed uptake of labeled octreotide in these lesions. In 5 of 17 (29%) patients whose tumors concentrated radioiodine, no uptake was found during SRS. CONCLUSIONS: 1) in patients with metastatic differentiated thyroid carcinoma, tumor sites can be visualized using SRS; 2) there is no need to withdraw patients from suppression therapy in order to perform SRS; 3) in some patients whose lesions do concentrate labeled octreotide but not radioiodine, the use of somatostatin analogues labeled with (111)In or [90Y] can provide new therapeutic options.
Authors: J Robbins; M J Merino; J D Boice; E Ron; K B Ain; H R Alexander; J A Norton; J Reynolds Journal: Ann Intern Med Date: 1991-07-15 Impact factor: 25.391
Authors: E P Krenning; R Valkema; P P Kooij; W A Breeman; W H Bakker; W W deHerder; C H vanEijck; D J Kwekkeboom; M deJong; S Pauwels Journal: Ital J Gastroenterol Hepatol Date: 1999-10
Authors: P T Postema; W W De Herder; J C Reubi; H Y Oei; D J Kwekkeboom; H J Bruining; J Bonjer; H van Toor; G Hennemann; E P Krenning Journal: Digestion Date: 1996 Impact factor: 3.216
Authors: Tatjana Traub-Weidinger; Daniel Putzer; Elisabeth von Guggenberg; Georg Dobrozemsky; Bernhard Nilica; Dorota Kendler; Reto Bale; Irene Johanna Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2015-07-15 Impact factor: 9.236
Authors: Marcel P M Stokkel; Henna I E Reigman; Robbert B T Verkooijen; Jan W Smit Journal: J Cancer Res Clin Oncol Date: 2003-05-15 Impact factor: 4.553
Authors: Michael Gabriel; Franz Froehlich; Clemens Decristoforo; Christian Ensinger; Eveline Donnemiller; Elisabeth von Guggenberg; Dirk Heute; Roy Moncayo Journal: Eur J Nucl Med Mol Imaging Date: 2003-11-19 Impact factor: 9.236
Authors: Rafay Ahmed; Matthew J Oborski; Misun Hwang; Frank S Lieberman; James M Mountz Journal: Cancer Manag Res Date: 2014-03-24 Impact factor: 3.989